thymic-factor--circulating and Uterine-Neoplasms

Indications have been received of cell immunity in 111 primary endometrial cancer patients in the process of complex treatment: hormonotherapy+surgery. These indices have revealed correlation with pathogenetic variants of disease. Suppression has also been registered of T-lymphocytes under the influence of complex treatment. 35 patients received thymic factor "Thymalin" as a component of complex treatment. Its positive effects on cell immunity and some clinico-morphological parameters have been registered.

Topics: 17 alpha-Hydroxyprogesterone Caproate; Adjuvants, Immunologic; Antineoplastic Agents; Cells, Cultured; Combined Modality Therapy; Estradiol; Female; Humans; Hydroxyprogesterones; Immunity, Cellular; Middle Aged; Rosette Formation; Survival Rate; T-Lymphocyte Subsets; Tamoxifen; Thymus Hormones; Uterine Neoplasms

Multifactorial analysis of effects of metabolic and endocrine determinants of the host and morphology of the tumor on cellular immunity has been undertaken in 29 patients with cancer of the corpus uteri. Several regression models obtained using the Hocking-Leslie method demonstrated significant effects of age, obesity, triglyceride levels, morphologic differentiation of the tumor and magnitude of invasion on various levels of cellular immunity, presenting as an increase in T-helper and decrease in suppressor counts. The multifactorial analysis depicted additive effects of endocrine homeostatic determinants and the tumor on different aspects of cellular immunity in cancer of the corpus uteri.

Topics: Age Factors; Aged; Female; Humans; Hypertriglyceridemia; Immune Tolerance; Leukocyte Count; Middle Aged; Obesity; Rosette Formation; T-Lymphocytes; Thymic Factor, Circulating; Thymus Hormones; Uterine Neoplasms

The results of a clinico-immunologic study of thymalin as a component of complex antitumor treatment of 21 cases of cancer of corpus uteri pointed to a pronounced immunomodulating action of the drug on T-cell-mediated immunity. It was inferred that thymalin should be used for immunocorrection in complex treatment for the said neoplasms provided T-cell-mediated immunity is monitored.

Topics: 17-alpha-Hydroxyprogesterone; Adjuvants, Immunologic; Combined Modality Therapy; Estradiol; Female; Humans; Hydroxyprogesterones; Middle Aged; Tamoxifen; Thymus Hormones; Uterine Neoplasms

Conditions for the reproducible measurement of thymic hormonal effect on the functional activity of human peripheral blood lymphocytes (PBL) were determined using a mixed lymphocyte-tumor culture assay. Three thymic hormonal preparations (thymopoietin, thymic humoral factor and TP-1) were tested by this assay and found to have a significant enhancing effect on the blastogenic response. Essential for the demonstration of the hormonal effect was the selection of suboptimal stimulation conditions, with the appropriate cell lines, including the number of stimulating cells and the time in culture. The most reproducible results were achieved when 1 x 10(5) PBL were co-cultured for 4 days with 1 x 10(4) mitomycin-C treated Raji lymphoma cells, after 1 h preincubation with one of the thymic preparations. However, strong enhancing effects of the thymic preparations could also be demonstrated with other tumor cel lines, especially IgR3 melanoma cells.

Topics: Adenocarcinoma; Burkitt Lymphoma; Carcinoma; Cell Line; Cells, Cultured; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Lymphocyte Activation; Lymphocytes; Melanoma; Thymic Factor, Circulating; Thymopoietins; Thymus Extracts; Thymus Hormones; Uterine Neoplasms